Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Sells $36,862.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the sale, the chief financial officer now owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Day One Biopharmaceuticals Stock Up 1.2 %

Shares of DAWN stock traded up $0.17 during trading on Monday, reaching $14.09. The company’s stock had a trading volume of 766,325 shares, compared to its average volume of 918,934. The business has a fifty day moving average price of $14.04 and a 200-day moving average price of $14.80. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -5.61 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a one year low of $9.67 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. Research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.29 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on DAWN shares. JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Finally, Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.71.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after buying an additional 472,654 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Day One Biopharmaceuticals by 34.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock worth $9,136,000 after buying an additional 159,341 shares during the last quarter. Braidwell LP lifted its stake in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after buying an additional 500,000 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Day One Biopharmaceuticals by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock worth $33,575,000 after buying an additional 336,281 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Day One Biopharmaceuticals by 20.5% during the 4th quarter. New York State Common Retirement Fund now owns 78,299 shares of the company’s stock worth $1,143,000 after buying an additional 13,294 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.